Geron (GERN)

• Market cap: $791M
• 1 day: 3.23%
• 5 days: -7.91%
• 1 month: 0.79%
• 3 months: 1.59%
• 6 months: 2.4%
• Year to date: -64.44%
• 1 year: -69.45%
• 5 years: -36%
• 10 years: -60.86%
• Sector: Healthcare
• Industry: Biotechnology

About: Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

Employees: 229